[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"CareAcross\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100643615","digital-support-for-multiple-myeloma-quality-of-life-100643615",false,"NCT07642362","Digital Support for Multiple Myeloma Quality of Life","Digital Support for Enhancing the Quality of Life of Patients With Multiple Myeloma: An Observational, Randomized, Prospective Study (DigiMyQoL)","DigiMyQoL","Inclusion Criteria:\n\n* Adult patients with newly diagnosed or relapsed\u002Frefractory multiple myeloma\n* Patients that are able to use the digital platform\u002Fapplication\n\nExclusion Criteria:\n\n* Patients that are not able to use the digital platform\u002Fapplication","ALL",{"count":19,"type":20},108,"ESTIMATED","INTERVENTIONAL",[23],"NA","The objective of this prospective study is to investigate the quality of life of patients with multiple myeloma and the effectiveness of support provided through a personalized web-based platform.\n\nSpecifically, the study will compare Patient-Reported Outcomes (PROs) and the associated improvement in side effects and quality of life achieved through appropriate personalized educational and supportive content.",[26,27,28,29],"Multiple Myeloma","Patient Reported Outcome (PRO)","Supportive Care in Cancer","Quality of Life",[31,32,33,34,35,36,37],"multiple myeloma","quality of life","qol","patient reported outcome","pro","digital oncology","supportive care","RECRUITING","2026-06-07",{"date":41,"type":42},"2026-06-11","ACTUAL",{"date":44,"type":42},"2025-02-27",{"date":46,"type":20},"2028-03",{"name":48,"class":49},"CareAcross","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":59,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100643192","study-of-the-impact-of-digital-health-interventions-on-symptom--side-effect-management-in-metastatic-sarcoma-patients-100643192","NCT07642375","Study of the Impact of Digital Health Interventions on Symptom & Side-Effect Management in Metastatic Sarcoma Patients","Observational, Randomized, Prospective Study of the Impact of Digital Health Interventions on Symptom and Side-Effect Management in Patients With Metastatic Sarcoma","SARC-Digital","Inclusion Criteria:\n\n* Age of ≥ 18 years.\n* Diagnosis of locally advanced or metastatic sarcoma of any location and origin.\n* Ability to understand and operate in a digital environment.\n* Patients planned to start standard of care treatment within the next month, or are currently undergoing standard of care treatment of any line.\n* Treatments include surgery, radiotherapy, chemotherapy, immunotherapy, targeted therapy, hormonal therapy, or any combination of the above.\n\nExclusion Criteria:\n\n* Limited ability or willingness to report side-effects on an online platform.\n* Performance status \\>3.\n* Life expectancy of \\\u003C6 months.\n* Participation in an interventional clinical trial with investigational drugs or devices.","18 Years",{"count":19,"type":20},[23],"The objective of this prospective study is to capture the quality of life of patients with locally advanced or metastatic sarcoma, and investigate the effectiveness of support provided through a personalized web-based platform.",[64,65],"Advanced Sarcoma","Metastatic Sarcoma",[36,32,33,67,68,37,69],"patient reported outcomes","PRO","digital therapeutics",{"date":41,"type":42},{"date":72,"type":42},"2023-08-22",{"date":74,"type":20},"2027-02",{"name":48,"class":49},11,""]